Dato-DXd 单药新辅助治疗策略在 HR(-)HER2(-)Im(-)DRD(-)乳腺癌亚组特别有效,总体安全性可控、耐受性良好。 参考文献 [1]Meghna S. Trivedi, et al. Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab ...
由我国研发的原创Ⅰ类新药泰它西普作为双靶点生物制剂也已应用于临床 ... recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus[J]. Drugs Today (Barc). 2022;58(1):23-32. 6.Dhillon S. Telitacicept: First ...